C4 Therapeutics : Corporate Presentation – February 2022

Delivering on the Promise of Targeted Protein Degradation

February 2022

Forward-looking Statements and Intellectual Property

Forward-looking Statements

The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should,"

"will," "would" and similar expressions. These forward-looking statements include, but are not limited to, statements

regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated

generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the

fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only

as of the date hereof. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in

this presentation, whether as a result of new information, future events or circumstances or otherwise.

Intellectual Property

C4 Therapeutics, Inc. owns various registered and unregistered trademarks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our

BIDAC and MONODAC degrader products. All trademarks or trade names referred to in this presentation that we do

not own are the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation are referred to without the symbols ® and ™, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

© 2022 C4 Therapeutics, Inc. |

2

Targeted Protein Degradation Has the Potential to Transform Treatment of Disease

	TPD Has an Expansive
	Target Landscape
~85%	85% of proteins are
	currently undruggable or

poorly drugged

TPD Offers a Powerful

Modality

Benefits of genetic knockdown with a small molecule approach

C4T's TORPEDO platform creates

therapeutic candidates that have the potential to improve patient care

Overcome Resistance

Drug Undruggable Targets

Improve Treatment Options

Source: Hopkins, A., Groom, C. The druggable genome. Nat Rev Drug Discov 1, 727-730 (2002).

© 2022 C4 Therapeutics, Inc. |

3

Our TORPEDO Platform Efficiently Designs Potent Targeted Protein Degrader Medicines

Elements

Benefits

Focus on Catalytic

Efficiency

Ability to Design, Analyze & Predict Degrader Performance

Investment in Cereblon as E3 Ligase

Ability to Develop Both MonoDAC & BiDAC Degraders

Optimization of overall degradation process results in maximal efficacy

Rapid delivery of potent drug candidates through informed and efficient drug discovery

Cereblon is expressed in all tissues and cellular compartments, thereby providing the largest target selection opportunity

Flexibility to address different targets with tailored approach

© 2022 C4 Therapeutics, Inc. |

4

C4T is Well Positioned to Deliver on the Promise of Targeted Protein Degradation to Transform Patient Care

Leading in	Validated	Oncology-Focused	Strong Foundation
TPD Science	Platform	Clinical Pipeline	to Support	Growth
World-class	TORPEDO platform	Transform patient	Capabilities across
enables efficient	discovery and
medicinal	care by targeting
optimization of	clinical coupled with
chemistry coupled	undrugged or
MonoDAC and	experience in
with fundamental	poorly drugged
BiDAC degraders	strategic
enzymology	targets
	partnerships and
approach
		strong balance
			sheet
			*Cash, cash equivalents, and
			marketable securities were
			$451.5M as of 12/31/21
			© 2022 C4 Therapeutics, Inc. |	5